IVA
Inventiva S.A.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
—
13F top-10 QoQ
Top fund weight
—
Inventiva S.A.
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
—
13F top-10 QoQ
Top fund weight
—
Inventiva S.A.
3.66
News
No N-PORT holders.
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Caligan PartnersCaligan Partners | $30.9M | 9.66% | +64.09% | |
| 2 | Samsara BioCapitalSamsara BioCapital | $23.9M | 7.47% | +21.56% | |
| 3 | Paradigm Biocapital AdvisorsParadigm Biocapital | $15.1M | 4.73% | 0.00% | |
| 4 | Andera PartnersAndera Partners | $13.7M | 4.30% | +99.83% | |
| 5 | ADAR1 Capital ManagementADAR1 | $13.6M | 4.27% | +65.87% | |
| 6 | Millennium ManagementMillennium | $13.3M | 4.16% | +17.56% | |
| 7 | Nantahala Capital ManagementNantahala | $10.2M | 3.18% | new | |
| 8 | Trails Edge Capital PartnersTrails Edge Capital Partners | $10.0M | 3.15% | 0.00% | |
| 9 | Franklin ResourcesFranklin Resources | $10.0M | 3.13% | +7.35% | |
| 10 | Squadron Capital ManagementSquadron | $9.2M | 2.88% | +355.14% | |
| 11 | Woodline PartnersWoodline Partners | $8.8M | 2.75% | new | |
| 12 | Standard Life AberdeenStandard Life Aberdeen | $8.7M | 2.73% | new | |
| 13 | UBS GroupUBS | $8.7M | 2.73% | −0.58% | |
| 14 | Boothbay Fund ManagementBoothbay Fund | $7.6M | 2.37% | +36.27% | |
| 15 | Patient Square CapitalPatient Square Capital | $7.4M | 2.33% | new | |
| 16 | NEXTBio Capital ManagementNEXTBio | $6.8M | 2.12% | +34.08% | |
| 17 | Citadel AdvisorsCitadel | $6.7M | 2.11% | +2647.60% | |
| 18 | Ameriprise FinancialAmeriprise Financial | $6.4M | 2.01% | +101.03% | |
| 19 | Point72 Asset ManagementPoint72 | $6.4M | 1.99% | +76.01% | |
| 20 | Integral Health Asset ManagementIntegral Health | $5.7M | 1.80% | +280.00% | |
| 21 | Yu FanYu Fan | $5.7M | 1.77% | 0.00% | |
| 22 | NEA ManagementNEA | $5.5M | 1.73% | 0.00% | |
| 23 | StemPoint CapitalStemPoint Capital | $5.4M | 1.69% | new | |
| 24 | Propel Bio ManagementPropel Bio | $4.8M | 1.52% | +76.80% | |
| 25 | Kingdon Capital ManagementKingdon | $4.8M | 1.50% | new |
No thesis.
88 managers report $319.5M of Inventiva on form 13F for the quarter ended Jun 30 '26. 27 of them hold 80% of it; Caligan Partners is largest at 9.66%.